Emiglitate (BAY o-1248) is a potent and competitive selective α-glucoside hydrolase inhibitor; it suppresses glucose-stimulated insulin release in vitro by inhibiting acid glucan-1,4-α-glucosidase and acid α-glucosidase activities; it abrogates CO-induced amplification of glucose-stimulated insulin release and increased acid α-glucoside hydrolase activities; in vivo, it induces a dose-dependent increase in hepatic glycogen concentrations in fasted rats due to lysosomal glycogen storage.